Financial Sense Advisors Inc. Has $1.16 Million Stock Holdings in Bausch Health Companies Inc. (NYSE:BHC)

Financial Sense Advisors Inc. decreased its position in Bausch Health Companies Inc. (NYSE:BHC) by 3.7% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 109,500 shares of the company’s stock after selling 4,150 shares during the period. Financial Sense Advisors Inc.’s holdings in Bausch Health Companies were worth $1,162,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in BHC. Principal Securities Inc. acquired a new position in Bausch Health Companies during the 4th quarter valued at about $31,000. Salem Investment Counselors Inc. bought a new stake in shares of Bausch Health Companies during the first quarter worth approximately $32,000. Tower Research Capital LLC TRC lifted its holdings in Bausch Health Companies by 283.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 6,918 shares of the company’s stock valued at $55,000 after buying an additional 5,112 shares during the period. Bfsg LLC bought a new position in Bausch Health Companies in the fourth quarter valued at approximately $63,000. Finally, Citigroup Inc. boosted its stake in Bausch Health Companies by 73.3% in the third quarter. Citigroup Inc. now owns 20,820 shares of the company’s stock valued at $172,000 after acquiring an additional 8,804 shares during the last quarter. 78.65% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

BHC has been the subject of several recent research reports. StockNews.com upgraded shares of Bausch Health Companies from a “hold” rating to a “buy” rating in a research report on Wednesday, May 15th. Royal Bank of Canada dropped their price objective on Bausch Health Companies from $12.00 to $11.00 and set a “sector perform” rating for the company in a report on Tuesday, April 23rd. Finally, Piper Sandler increased their target price on Bausch Health Companies from $7.00 to $9.00 and gave the company a “neutral” rating in a research note on Monday, April 29th.

Bausch Health Companies Trading Up 0.6 %

BHC opened at $7.15 on Thursday. The stock has a market capitalization of $2.58 billion, a P/E ratio of -5.77 and a beta of 0.77. Bausch Health Companies Inc. has a 12 month low of $6.05 and a 12 month high of $11.46. The firm’s fifty day simple moving average is $6.91 and its 200 day simple moving average is $8.08.

Bausch Health Companies (NYSE:BHC) last released its quarterly earnings results on Thursday, May 2nd. The company reported $0.59 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.75 by ($0.16). The firm had revenue of $2.15 billion during the quarter, compared to analyst estimates of $2.18 billion. Bausch Health Companies had a negative net margin of 5.07% and a negative return on equity of 2,370.91%. On average, equities research analysts predict that Bausch Health Companies Inc. will post 3.63 EPS for the current fiscal year.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.